These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 11887489)

  • 1. Hyporesponse to Epoetin alfa: patients at risk. Case study of the anemic patient.
    Deziel SM
    Nephrol Nurs J; 2002 Feb; 29(1):60-3. PubMed ID: 11887489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
    Patton J; Kuzur M; Liggett W; Miranda F; Varsos H; Porter L
    Oncologist; 2004; 9(1):90-6. PubMed ID: 14755018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing hyporesponse to Epoetin alfa: an algorithm approach: case study of the anemic patient.
    Wingard R
    Nephrol Nurs J; 2000 Oct; 27(5):517-20. PubMed ID: 16649327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N; Sriuranpong V; Suwanrusme H
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timely correction of anemia at the initiation of dialysis. Case study of the anemic patient.
    Breiterman-White R
    Nephrol Nurs J; 2002 Oct; 29(5):469-72. PubMed ID: 12434453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes.
    Collins AJ; Brenner RM; Ofman JJ; Chi EM; Stuccio-White N; Krishnan M; Solid C; Ofsthun NJ; Lazarus JM
    Am J Kidney Dis; 2005 Sep; 46(3):481-8. PubMed ID: 16129210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anemia management practices in peritoneal dialysis patients. Case study of the anemic patient.
    MacCracken MA
    Nephrol Nurs J; 2001 Aug; 28(4):435-8. PubMed ID: 12143466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life in patients on dialysis: benefits of maintaining a hemoglobin of 11 to 12 g/dL.
    Gregory N
    Nephrol Nurs J; 2005; 32(3):307-10. PubMed ID: 16035472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy.
    Littlewood TJ; Nortier J; Rapoport B; Pawlicki M; de Wasch G; Vercammen E; Schuette W; Wils J; Freund M;
    Hematol Oncol; 2003 Dec; 21(4):169-80. PubMed ID: 14735555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa.
    Lefebvre P; Vekeman F; Sarokhan B; Enny C; Provenzano R; Cremieux PY
    Curr Med Res Opin; 2006 Oct; 22(10):1929-37. PubMed ID: 17022852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.
    Leyland-Jones B; Semiglazov V; Pawlicki M; Pienkowski T; Tjulandin S; Manikhas G; Makhson A; Roth A; Dodwell D; Baselga J; Biakhov M; Valuckas K; Voznyi E; Liu X; Vercammen E
    J Clin Oncol; 2005 Sep; 23(25):5960-72. PubMed ID: 16087945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.
    Chang J; Couture F; Young S; McWatters KL; Lau CY
    J Clin Oncol; 2005 Apr; 23(12):2597-605. PubMed ID: 15452188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revisions in the prescribing information for Epoetin alfa: implications for nephrology nurses and patients on dialysis.
    Hayslip D
    Nephrol Nurs J; 2008; 35(2):163-7. PubMed ID: 18472685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic anemia and fatigue in elderly patients: results of a randomized, double-blind, placebo-controlled, crossover exploratory study with epoetin alfa.
    Agnihotri P; Telfer M; Butt Z; Jella A; Cella D; Kozma CM; Ahuja M; Riaz S; Akamah J
    J Am Geriatr Soc; 2007 Oct; 55(10):1557-65. PubMed ID: 17697104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years.
    Jacobs C; Frei D; Perkins AC
    Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii3-24. PubMed ID: 15824128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.
    Crawford J; Cella D; Cleeland CS; Cremieux PY; Demetri GD; Sarokhan BJ; Slavin MB; Glaspy JA
    Cancer; 2002 Aug; 95(4):888-95. PubMed ID: 12209734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anemia of cancer patients: patient selection and patient stratification for epoetin treatment.
    Ludwig H; Fritz E
    Semin Oncol; 1998 Jun; 25(3 Suppl 7):35-8. PubMed ID: 9671328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemorheological and hemodynamic changes in predialysis patients after normalization of hemoglobin with epoetin-alpha.
    Furuland H; Linde T; Sandhagen B; Andrén B; Wikström B; Danielson BG
    Scand J Urol Nephrol; 2005; 39(5):399-404. PubMed ID: 16257842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.